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Abstract: Regions of the Herpes simplex virus-1 (HSV-1) glycoprotein D (gD) were chosen to design
carrier peptides based on the known tertiary structure of the virus entry receptor complexes. These
complexes consist of the following: HSV-1 gD–nectin-1 and HSV-1 gD–herpesvirus entry mediator
(HVEM). Three sets of peptides were synthesised with sequences covering the (i) N-terminal
HVEM- and nectin-1 binding region -5–42, (ii) the 181–216 medium region containing nectin-1
binding sequences and (iii) the C-terminal nectin-1 binding region 214–255. The carrier candidates
were prepared with acetylated and 5(6)-carboxyfluorescein labelled N-termini. The peptides were
chemically characterised and their conformational features in solution were also determined. In vitro
internalisation profile and intracellular localisation were evaluated on SH-SY5Y neuroblastoma
cells. Peptide originated from the C-terminal region 224–247 of the HSV-1 gD showed remarkable
internalisation compared to the other peptides with low to moderate entry. Electronic circular
dichroism secondary structure studies of the peptides revealed that the most effectively internalised
peptides exhibit high helical propensity at increasing TFE concentrations. We proved that oligopeptides
derived from the nectin-1 binding region are promising candidates—with possibility of Lys237Arg
and/or Trp241Phe substitutions—for side-reaction free conjugation of bioactive compounds—drugs or
gene therapy agents—as cargos.
Keywords: carrier peptide; HSV-1 gD glycoprotein; Nectin-1; Herpesvirus entry mediator; cellular
uptake; intracellular localisation; helical propensity; structure – activity studies
1. Introduction
Applications of virus-derived peptides have been described in various fields such as targeted
drug and gene transport strategies, development of vaccines, diagnostics and imaging techniques [1–3].
Viruses considered to be pathogenic to humans and other organisms can be promising tools due to their
unique characteristics of mastering the ability to enter different target cells efficiently and to overcome
all the barriers present both in the cells and the host organism. The virus-derived carrier peptides are
suitable multifunctional vehicles for the transportation of various compounds to target cells.
The Herpesviridae family consists of various viruses: among the human herpes viruses (HHV) the
Herpes simplex virus (HSV) 1 and 2, and the Varicella zoster virus (VZV) belong to the α-Herpesvirinae;
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cytomegalovirus (CMV), HHV 6A, 6B and 7 to β-Herpesvirinae; rhadinoviruses like Epstein-Barr virus
(EBV) and Kaposi’s sarcoma associated virus to the γ-Herpesvirinae. HSV-1 infection causes cold sores
and ulcers on the face. These symptoms, in most cases, clear with the help of presently available topical
treatment, but the virus becomes latent in the cells of peripheral nervous system and is frequently
reactivated. During reactivation, the virus is transported via the axons of the neurons to the skin
causing new sores. In certain cases, serious complications may arise affecting the nervous system
(encephalitis, meningitis).
The Herpesviridae have relatively large (120–200 kb), double-stranded linear DNA genome within an
icosahedral capsid, which is in a lipid bilayer envelope covered with membrane bound glycoproteins [4].
Five HSV envelope glycoproteins are participating in the Herpes simplex virus entry, gC, gB, gD and the
heterodimer gH/gL. Among these the role of gD glycoprotein is unique among the Herpes viruses [5].
The ectodomain of HSV-1 gD glycoprotein contains a compact Ig-like β-sandwich domain (residues 56
– 184) which is wrapped by α-helices, strands and several loops consisting of the N-terminal (residues
P23 to I55) and C-terminal (residues A185 to E259) extensions [6], the 1–22 region was not crystallisable.
During virus entry, after tethering the virus by nonspecific interactions of gC and gB to the host
cell surface, interaction between the receptor-binding protein gD and a specific cell surface receptor
(herpesvirus entry modulator A (HVeA or HVEM) or nectin-1) follows. During the binding process,
the structure of gD undergoes changes, the 50 residues long C-terminal pro-fusion domain (residues
T260 to A310), previously wrapped on the protein [7,8], unfolds, and nectin-1 [6,9] or HVEM [10] binds
to the new surface left exposed by this domain. The receptor binding by gD follows gD’s binding to
gB [11], triggering the membrane fusion process that is mediated by gB and gH/gL [5,12].
Recombinant HSV-1 gD 1-285 protein was co-crystallised with recombinant nectin-1 [6,9] and
HVEM [10] proteins. According to Di Giovine et al. (3SKU) [9] and Zhang et al. (3U82) [6], the nectin-1
binding sites of HSV-1 gD are mainly located in the terminal extensions, with only a few residues of
the Ig-like domain and two short regions near the N-terminus making contact with nectin-1. From the
part of nectin-1 the C”C’CFG β-sheet is the main participant in this contact. In the study of Carfi et al.
(1JMA) [10], it is shown that HVEM is bound to parts of the N-terminal 1-37 hairpin structure of HSV-1
gD. The binding interface of HSV-1 gD with HVEM (1JMA) and the first domain of nectin-1 in complex
with HSV-1 gD (3U82) is shown on Figure 1A.
The importance of gD glycoprotein has been demonstrated by Cocchi et al. in 2004 [13] by gD-null
mutant non-infecting virus. Infectivity was restored by adding to the gD-null mutant viruses either
the soluble ectodomain of gD or mutant virus-bound gDs containing both the receptor binding region
and the profusion domain.
Glycoprotein gD also plays an important role in cell-to-cell spread of the infection,
Krummenacher et al. has shown that newly expressed gD accumulates on the surface of infected cells
near neighbouring, uninfected cells bearing nectin-1 [14].
The gH glycoprotein has been extensively studied for effective targeting peptides, and the 20mer
gH 625HGLASTLTRWAHYNALIRAF644 forming an amphiphilic helix when in connection with lipid
membranes, is able to non-specifically deliver cargo molecules, even proteins, across cell membranes
more efficiently than polycationic cell penetrating peptides (e.g., Tat) [15]. The same peptide used in the
form of dendrimers proved that the cellular entry is based on pore formation, avoiding endocytosis [16].
In this study, our aim was to design carrier peptides based on the entry process of HSV-1 involving
gD glycoprotein – HVEM – nectin-1 complex. The sequences of the peptides were derived from the gD
glycoprotein of HSV-1, by using sets of overlapping sequences based on the structure and interaction
of the entry complex’ proteins described in the studies above [6,9,10]. The designed sequences of
the peptides are mainly based on the regions originated from HSV-1 gD in close proximity of either
nectin-1 or HVEM (Figure 1B). We postulated that certain peptides possess the ability to internalise
into cells and can also be used as delivery vehicles.
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Figure 1. (a) Structure of HVEM – HSV-1 gD complex (1JMA) and the first domain of nectin-1 in 
complex with HSV-1 gD (3U82) with the binding interface shown in ribbon model. Similar 
orientation of the HSV-1 gD protein has been intended, but the conformation of the protein is not 
identical in the different complexes. (b) Localisation of the regions defining the four peptide sets 
(I-IV) designed for synthesis based on the sequence of HSV-1 gD glycoprotein (PDB ID: 1JMA). 
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2. Materials and Methods
2.1. Materials
9-Fluorenylmethoxycarbonyl (F oc) protected amino acid derivatives and Rink amide
4-methylbenzhydrylamine (Rink amide MBHA) resin were purchased from IRIS Biotech GmbH
(Marktredwitz, Germany). The reagents for synthesis were N,N’-diisopropylcabodiimide (DIC),
N,N-diisopropyl-ethylamine (DIEA), 1-hydroxybe zotriazole (HOBt), 1,8-diazabicyclo-[5.4.0]undec-
7-ene (DBU), piperidine, thioanisol, phenol, 1,2-ethanedithiol, 5(6)-carboxyfluorescein (Cf), and they
were purchased from Sigma-Aldrich (Budapest, Hungary). Trifluoroacetic acid (TFA) and solvents
(N,N-dimethylformamide (DMF) a d dichloromethane) (DCM)) for synthesis, as well as HPLC grade
acetonitrile, were obtained from Molar Chemicals (Halásztelek, Hungary). Cf-Penetratin was provided
by Kata Horváti (MTA-ELTE Research Grou of Peptide Chemistry; Eötvös Loránd University, Institute
of Chemistry) [17,18].
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2.2. Peptide Synthesis
Eleven 20mer peptides derived from the HSV-1 gD (from HSV-1 gD regions -5–23, 181–216 and
228–255) were prepared by multipin solid phase synthesis method on Rink amide linker functionalised
Mimotopes cleavable lanterns (Mimotopes, Clayton, Australia) [19] with Fmoc/tBu strategy on 8
micromolar scale, in duplicates. After the completion of the synthesis, one copy of all the peptides was
labelled with 5(6)-carboxyfluorescein (Cf) on their N-termini, the other copy was acetylated, and then
the peptides were cleaved from the lanterns by TFA – thioanisol – water – phenol – 1,2-ethanedithiol
(80:5:5:7.5:2.5, v/v/v/m/v) cleavage mixture removing the side chain protecting groups as well, except the
acetamidomethyl groups from Cys residues of Set II peptides. The rest of the peptides were prepared
on Rink-amide MBHA resin, partly on a Syro-I automated peptide synthesiser (Biotage, Uppsala,
Sweden); Cf-(228–243) and its Lys→ Arg / Trp→ Phe modified versions, the truncated Cf-(228–243 F)
and the Cf-(10–33) peptide and its N- and C-terminal decamer fragments were prepared manually
with resin portioning on a 0.05 millimolar scale. Acetylated and Cf-labelled versions were prepared,
and the peptides were cleaved from the resin with the above cleavage mixture. In case of sequences
214–233 and 219–238 the methionine residue has been substituted by norleucine. The peptides were
purified by RP-HPLC on a Knauer HPLC system (Berlin, Germany) on Phenomenex Jupiter C18
column (10 µm, 300 Å, 10 mm × 250 mm). The purity and identity of the products were studied with
RP-HPLC and ESI-MS.
2.3. Stability Studies of Synthetic Peptides
Before the cellular uptake studies the stability of the Cf-labelled synthetic peptides was determined.
Peptides were dissolved at 1 mg/mL concentration in serum-free DMEM medium (Lonza, Basel,
Switzerland), and incubated at 37 ◦C for 24 h. Samples for RP-HPLC (Knauer, Berlin, Germany) were
taken at 0, 3, 6 and 24 h. Phenomenex Luna C18 column (5 µm, 300 Å, 4.6 mm × 250 mm) (Gen-Lab
Ltd., Budapest, Hungary) was applied with a gradient of 0–5 min 5% B eluent elevated to 55% B during
25 min, where eluent A: 0.1% TFA/water, eluent B: 0.1% TFA/acetonitrile–water 80:20 (v/v).
2.4. Fluorescence Spectroscopy of the 5(6)-Carboxyfluorescein Labelled Peptide Derivatives
The fluorescence properties of the Cf-peptides were studied at different pH values with fluorescence
spectroscopy using Varian Cary Eclipse fluorimeter (the method was first described in [20]). Briefly:
peptides were dissolved in 0.1 M citrate phosphate buffer (pH = 4.0, 5.0, 6.0, 7.0); and 0.4 µm peptide
concentration was used. Excitation wavelength was λ = 488 nm (corresponding to the laser of the flow
cytometer). Detection was in the range of 500–700 nm.
2.5. Secondary Structure Prediction
For the 3D visualisation of the secondary structure of HSV-1 gD peptides PEP-FOLD3 prediction
was used [21], number of simulations: 100, sorted by sOPEP score [22].
2.6. Electronic Circular Dichroism (ECD) Spectroscopy
ECD spectra of acetylated HSV peptides were recorded using a Jasco J-810 and Jasco J-715
spectropolarimeter (Jasco Corporation, Tokyo, Japan) in the λ = 180–270 nm wavelength range using
a 0.02 or a 0.1 cm path length quartz cell at room temperature, under constant nitrogen flush with
continuous scanning mode. All spectra reported here were obtained as an average of three or five
individual scans and corrected with the solvent ECD spectra. The J-810 equipment was calibrated with
ammonium α-10-camphor-sulfonate. The samples were dissolved in trifluoroethanol (TFE) (Sigma),
distilled water and a 1:1 (v/v) mixture of TFE:water. The solution concentration was in the range of
0.5–0.7 mg/mL (J-810) or ~0.14 mg/mL (J-715) for peptide amides. ECD band intensities are expressed
in mean residual molar ellipticity unit. The percentage of the different conformational elements
contributing to the ECD spectra was calculated by the MS Excel version of the PEPFIT program
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developed originally by Reed and Reed [23,24]. The algorithm estimates the percentage of secondary
contents by fitting experimental ECD data to the combination of reference spectra. The best fit is
defined by the R2 value, where an R2 = 1 corresponds to a perfect match.
2.7. Cell Culturing and Cellular Uptake Studies
The SH-SY5Y cells were kindly provided by Dr. Zsolt Datki (Department of Medical Chemistry,
University of Szeged) [25–28] and maintained as adherent cultures in DMEM (Lonza™) supplemented
with 10% heat-inactivated fetal calf serum (FCS, Lonza™), L-glutamine (2 mM), 1% non-essential
amino acids (Sigma), 1 mM sodium pyruvate (Sigma), and penicillin-streptomycin antibiotics mixture
(Lonza™ BioWhittaker™, 5000 IU/5000 IU). Cells were grown in sterile T25 or T75 flasks with
ventilation cap (Sarstedt, Nümbrecht, Germany) at 37 ◦C in a humidified atmosphere with 5% CO2.
Prior to experiments SH-SY5Y cells were seeded into 24-well plates (Sarstedt) in DMEM medium
(supplemented as described above), 5 × 104 cells/well in 1 mL and cultured overnight at 37 ◦C, 5%
CO2. After centrifugation for 5 min at 1000 rpm the medium was removed, 5(6)-carboxyfluorescein
labelled peptides have been added in serum-free DMEM at the concentration range of 0.4 – 50 or
250 µM in 400 µL/well, and incubated for 3 h (37 ◦C, 5% CO2). Then the cells were washed twice with
serum-free DMEM. After the washing steps all supernatant was removed, and 100 µL 0.25% trypsin
(Sigma-Aldrich) was added to the cells. After 5 min incubation, 0.8 mL 10% FCS/HPMI medium
was added (HPMI buffer contained 9 mM glucose, 10 mM NaHCO3, 119 mM NaCl, 9 mM HEPES,
5 mM KCl, 0.85 mM MgCl2, 0.053 mM CaCl2, 5 mM Na2HPO4 × 2H2O, pH 7.4 [23]) and the cells were
transferred into FACS tubes (Sarstedt), centrifuged again. After centrifugation cells were resuspended
in 250 µL HPMI, and the cellular uptake of the peptides was analysed by measuring the intracellular
fluorescence on a BD LSR II flow cytometer (excitation: λ = 488 nm (Coherent Sapphire laser), emission
channel: LP510). The resulting intracellular fluorescence intensity data were evaluated by FACSDiva
5.0 software.
2.8. Intracellular Localisation Studies using Confocal Laser Scanning Microscopy
SH-SY5Y cells were seeded into coverslips (thickness 1, Assistent®, Karl Hecht GmbH & Co KG,
Sondheim vor der Rhön, Germany) containing 24-well plates (Sarstedt) for microscopy studies at a
density of 7.5 x 104 cells/well, in 1 mL complete DMEM medium. The following day, cells were treated
with Cf-HSV peptides at a concentration of 25 µM (diluted in serum free DMEM medium) for 3 h.
Lysosomes were stained with Lysotracker Deep Red (Thermo Fisher Scientific, Waltham, MA, USA)
according to the manufacturer’s instructions. Nuclei were visualised with Hoechst 33342 (Thermo
Fisher Scientific, 0.2 µg/mL). After each step, cells were washed three times with serum-free medium.
Following the staining and washing steps, cells were fixed with 4% paraformaldehyde (Sigma-Aldrich,
Budapest, Hungary), the solution was prepared in-house, washed with PBS (pH = 7.4). The coverslips
were mounted with Mowiol 4–88 (Sigma-Aldrich, Budapest, Hungary) to microscopy slides. Imaging
was performed by a Zeiss LSM-710 system (Carl Zeiss microscopy GmbH, Oberkochen, Germany)
with a 40×/1.4 Plan-Apochromat oil immersion objective using lasers with excitation maxima 405, 488
and 633 nm for detecting Hoechst, Cf-conjugated peptides and LysoTracker, respectively. Images were
processed with ZEN (Carl Zeiss microscopy GmbH).
3. Results
3.1. Synthesis and Characterisation of HSV-1 gD Peptides
Peptides to be synthesised for ECD spectroscopic structural and cellular uptake studies were
selected using the known X-ray structure of HSV-1 gD – nectin-1 complex (3U82) [6,9] and that of
the HSV-1 gD – HVEM complex (1JMA) (Figure 1A) [10]. Peptide regions were selected based on the
regions of HSV-1 gD contacting either nectin-1 or HVEM according to the above complex structures,
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elongated towards non-contacting regions. Thus, overlapping peptides from the HSV-1 gD -5–42,
181–216 and 214–255 regions were selected (Figure 1B).
Twenty-eight peptide sequences corresponding to the nectin-1/HVEM binding site of HSV-1 gD
glycoprotein were synthesised on solid phase, either labelled with 5,6-carboxyfluorescein or acetylated,
cleaved from the resin, purified by RP-HPLC and identified with ESI-MS (MS spectra of Cf-peptides are
presented in the Supplementary information, Figures S1–S4). The acetamido protecting group has not
been removed from peptides containing Cys residues to prevent oxidation and to mimic the disulphide
bond within the protein. The peptides obtained were of more than 95% purity. The code, structure
and analytical data of the Cf-labelled peptides are shown in Table 1. Peptides designed for secondary
structure studies were acetylated, their analytical data are shown in Table S1 of Supplementary
information. The numbering of the peptide sequences is according to the protein lacking the signal
sequence; two peptides from the N-terminal of the HSV-1 gD contain 1–5 amino acids from the signal
region have negative numbering.
Some of the Set I peptides contained methionine residue. Methionine in Set III peptides was
replaced by norleucine, with identical side chain size, but the sulphur atom is replaced by a methylene
group, because the methionine is sensitive for oxidation. In Set IV aromatic side chain of oxidatively
sensitive tryptophan was changed by phenylalanine; and the basic lysine was replaced by the similar,
but less reactive arginine.
Table 1. Analytical evaluation of Cf-labelled HSV-1 gD synthetic peptides.




Cf-(-1–19) Cf--1GKYALADASLKMADPNRFRG19 2538.8/2539.0 17.5
Cf-(4–23) Cf-4LADASLKMADPNRFRGKDLP23 2572.8/2572.8 91.9
Cf-(10–33) Cf-10KMADPNRFRGKDLPVLDQLTDPPG33 3038.4/3038.5 40.3
Cf-(10–19) Cf-10KMADPNRFRG19 1548.7/1548.6 35.1
Cf-(24–33) Cf-24VLDQLTDPPG33 1411.5/1410.8 31.6
Cf-(20–39) Cf-20KDLPVLDQLTDPPGVRRVYH39 2676.0/2675.1 23.0




Cf-(185–204) Cf-185AKGSCKYALPLRIPPSACLS204 2575.0/2575.5 92.9
Cf-(189–208) Cf-189CKYALPLRIPPSACLSPQAY208 2691.1/2691.0 96.6
Cf-(193–212) Cf-193LPLRIPPSACLSPQAYQQGV212 2566.9/2566.9 115.4




Cf-(219–238) Cf-219M*LPRFIPENQRTVAVYSLKI238 2715.1/2713.8 12.2
Cf-(224–243) Cf-224IPENQRTVAVYSLKIAGWHG243 2596.8/2596.1 6.6
Cf-(224–239) Cf-224IPENQRTVAVYSLKIA239 2159.4/2159.0 23.7
Cf-(228–247) Cf-228QRTVAVYSLKIAGWHGPKAP247 2536.9/2537.2 4.7
Cf-(228–243) Cf-228QRTVAVYSLKIAGWHG243 2143.4/2143.3 6.5
Cf-(232–251) Cf-232AVYSLKIAGWHGPKAPYTST251 2504.8/2505.0 18.0




Cf-(228–243 F) Cf-228QRTVAVYSLKIAGFHG243 2104.3/2104.4 8.9
Cf-(229–243 F) Cf-229RTVAVYSLKIAGFHG243 1976.2/1975.6 12.7
Cf-(230–243 F) Cf-230TVAVYSLKIAGFHG243 1820.0/1819.1 19.1
Cf-(231–243 F) Cf-231VAVYSLKIAGFHG243 1718.9/1718.5 14.7
Cf-(228–243 R) Cf-228QRTVAVYSLRIAGWHG243 2171.4/2171.3 6.7
Cf-(228–243 RF) Cf-228QRTVAVYSLRIAGFHG243 2132.3/2132.0 6.0
All Cf-peptides were amidated on the C-terminus and isolated as TFA salt. a Bruker Esquire 3000+ ESI MS mass
spectrometer. b UC50: interpolated concentration required for intracellular fluorescence in 50% of the cell. c M*:
methionine norleucine exchange, F: Trp241Phe, R: Lys237Arg exchange.
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Peptide amides prepared manually by multipin synthesis on Mimotopes lanterns (Figure S5)
proved to be similar in quality as peptides prepared on Syro-I automated peptide synthesiser
(Figure S6). The 8 µmolar scale of the crude Cf-labelled 20mer peptides was sufficient for purification,
characterisation and cellular uptake studies; therefore, preliminary screening of even 96 peptides
would be feasible with this method for laboratories without access to automated synthesiser. For
further studies of lead peptides larger scale synthesis is practical. Total manual synthesis on resins is
also useful for families of peptides (amino acid replacement, N-terminal truncation) with resin division
(Figure S7).
The Cf-labelled HSV-1 gD peptides were characterised by their fluorescence spectra as well.
Fluorescence intensity spectra of Set III peptides are shown in Figure 2. At pH = 4.0 all Cf-peptides
showed an average of 93% decrease in fluorescence intensity compared with that measured at pH = 7.0,
a characteristic feature of 5(6)-carboxyfluorescein. In case of lysosomal localisation of peptides,
therefore, the intracellular fluorescence would be negligible. The fluorescence intensity in the case
of most peptides at identical pH varied with cc. 1:2 ratio between the ones with the lowest and
the highest fluorescence, with the exception of peptides Cf-(228–243 F) and Cf-(224–243) with lower
fluorescence, and most notably Cf-(219–238). The latter showed only 13% fluorescence intensity
compared to the average maximum intensity. Fluorescence intensity spectra (at pH = 4.0 – 7.0) of all
peptides can be seen in the Supplementary information (Figures S8–S11). The position of the maximum
emission wavelength did not vary more than 2 nm; therefore, the Cf-labelled peptides are suitable for
comparative analysis in flow cytometry.
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Figure 2. Fluorescence emission spectra of (A) peptide Cf-(228–247) at different pH values and of (B)
Set III Cf-HSV peptides from the 214–255 region of HSV-1 gD (pH = 7.0).
The stability of the Cf-labelled peptides was studied in serum-free DMEM medium for 0, 3, 6 and
24 h at 37 ◦C. Peptides containing methionine residues have been partly oxidised within 3 hours, and
completely within 24 hours, other peptides proved to be stable under these circumstances, except for a
slight decrease in the intensity of the peak corresponding to the intact peptide at 24 h. As an example,
HPLC chromatograms of the peptides Cf-(228–247) and Cf-(236–255) are shown in the Supplementary
information (Figure S12).
3.2. Secondary Structure Studies Using Electronic Circular Dichroism Spectroscopy
Electronic circular dichroism (ECD) is a widely employed, non-destructive spectroscopic technique
for rapid evaluation of the secondary (far-UV region) and tertiary (near-UV region) structure of peptides
and proteins [29]. Therefore, ECD spectroscopy measurements were performed in the far-UV region
on selected acetylated HSV-1 gD peptides in TFE, water and TFE-water 1:1 (v/v) solutions. In all cases,
the ECD curves obtained in water displayed a negative band centred about λ = 195-200 nm and a less
intense negative shoulder above λ = 215 nm (Figure 3). Such a spectral pattern is characteristic of the
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major contribution of disordered conformational state (Table 2) which is in line with the results of
crystallographic studies. The N-terminal region of the glycoprotein (residues 7–15 and 24–32) was
extended and partly disordered when the gD ectodomain was crystallised alone [9,10]. Similarly, no
electron density was observed for residues 251 to 285 [7,9]. It is to be noted that the λmax of some
peptides was red shifted by cc. 1-2 nm and the short-wavelength tail of the negative band reached
the zero baseline instead of showing a local minimum (Figure 3). In accord to these spectral features,
the secondary structure analysis indicated a small helical contribution for Ac-(219–238), Ac-(224–243),
Ac-(214–233), and Ac-(-1–19) (Table 2).
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Figure 3. Far-UV CD spectra of HSV peptides measured in water (black), TFE (red) and water:TFE (1:1
v/v) mixture. Arrows denote isodichroic points at λ ~203 nm. For Ac-(214–233), the isodichroic point is
shifted to λ = 206 nm.
In relation to water, ECD curves registered in water:TFE and pure TFE solutions exhibited dramatic
alterations f r most peptides. The spectra consist of an intense, positive-negative band pair centred at
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λ ~192 / ~208 nm and a weaker, broad negative band with a λmin between λ = 220–230 nm (Figure 3).
According to the coupled oscillator theory, the short-wavelength positive and the longer-wavelength
negative ECD peak stem from exciton splitting of the π-π* transition of the amide bonds forming a
right-handed helix whereas the negative band at λ = 220–222 nm is of n-π* origin [29]. This pattern
clearly indicates that the peptides are stabilised in helical conformation which is the consequence of
the helix promoting effect of the membrane-mimetic TFE [30,31]. Therefore, it can be proposed that the
helical conformations observed here resemble those assumed by the peptide in a cell membrane.
Superimposition of the CD curves obtained in water, TFE and their 1:1 mixture shows a clean
conserved isodichroic point near λ = 203 nm for most peptides (Figure 3), which is indicative of a
two-state transition from a disordered to highly helical conformation [31].
Table 2. Estimation of the secondary structure fraction of acetylated HSV peptides. Far-UV CD
spectroscopic data were analysed by using the MS Excel version of the PEPFIT program. Values in
bracket show the helical content obtained with the formula of Chen and Yang [32]. M*: methionine
residue has been substituted by norleucine.
H2O H2O:TFE TFE H2O H2O:TFE TFE
-5HGVRGKYALADASLKMADPN15 -1GKYALADASLKMADPNRF19
α-helix 0 (3) 39 (33) 66 (60) 8 (7) 50 (42) 70 (56)
β-sheet 15 0 0 4 0 0
disordered 70 30 2 64 10 0
turn 15 31 32 24 40 30
R2 0.9833 0.9961 0.9952 0.9931 0.9909 0.9804
214VDSIGM*LPRFIPENQRTVAV233 219M*LPRFIPENQRTVAVYSLKI238
α-helix 6 (7) 18 (22) 36 (28) 8 (5) 48 (51) 68 (76)
β-sheet 0 8 0 0 20 19
disordered 74 40 36 78 26 2
turn 20 34 28 14 6 11
R2 0.9819 0.9957 0.9916 0.9810 0.9954 0.9921
224IPENQRTVAVYSLKIAGWHG243 228QRTVAVYSLKIAGWHGPKAP247
α-helix 8 (3) 73 (72) 92 (89) 0 (3) 48 (41) 78 (57)
β-sheet 22 20 8 0 0 0
disordered 70 7 0 73 38 0
turn 0 0 0 27 14 22
R2 0.9747 0.9950 0.9957 0.9863 0.9945 0.9939
232AVYSLKIAGWHGPKAPYTST251 236LKIAGWHGPKAPYTSTLLPP255
α-helix 0 (0) 32 (18) 41 (25) 0 (0) 6 (5) 15 (10)
β-sheet 0 8 0 0 4 0
disordered 48 52 42 60 60 64
turn 52 8 17 40 30 21
R2 0.9950 0.9800 0.9776 0.9767 0.9920 0.9942
228QRTVAVYSLKIAGFHG243
α-helix 0 (0) 56 (52) 82 (67)
β-sheet 20 20 2
disordered 68 10 4
turn 12 14 12
R2 0.9841 0.9889 0.9872
In stark contrast to the other peptides, the ECD spectrum of Ac-(236–255) reflected only minor
conformational changes upon increase of the TFE concentration indicating no ordered secondary
structure even in pure TFE solution (Figure 3). Presumably, this result is related to the abundance of
the strongly disorder-promoting proline residues in the peptide sequence (Table 2).
Ac-(224–243), Ac-(231–243 F) and Ac-(228–247) showed the highest α-helical content (80–90%)
suggesting that these sequences readily adopt helical conformation upon interaction with lipid
membranes (Table 2). The helical content of the peptides in different solvents was also estimated
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employing the simple equation formulated by Chen and Yang: f H = -([Θ]222 + 2340)/30,300 where
f H the fraction of helix and [Θ]222 is the measured mean residual ellipticity at 222 nm [32]. It seems
that the helical fractions obtained correlate favourably with the results of the curve fitting procedure
(Table 2).
Based on the visual comparison of the ECD curves taken in TFE and TFE-water mixture, the greatest
helical propensity can be predicted for Ac-(224–243), Ac-(228–243 F), Ac-(228–247) and Ac-(219–238)
(Figure 3). The ECD magnitudes of these peptides are close to each other in these solvents. The
helical propensity can be further evaluated by the calculation of the ratio of mean residue ellipticities,
Θ222 nm/Θ208 nm, which is a useful diagnostic parameter. For single stranded α-helices, this value falls
between 0.8 and 0.95, whereas above 1 it is symptomatic to the presence of coiled-coil motifs [33]. For
HSV peptides showing helical folding, this ratio is ranged within 0.6–0.9 indicating helix formation
but not the intermolecular association of the chains (Figure 4).Biomolecules 2020, 10, 11 of 21 
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The peptide structure was also analysed using the PEP-FOLD3 (PEP-FOLD server 2017)
service [21,34,35]. PEP-FOLD3 is a de novo approach for predicting the 3D structure, based on
structural alphabet (SA) letters to describe the conformations of four consecutive residues followed
by the coupling of the predicted series of SA letters to a greedy algorithm and a coarse-grained force
field [36,37]. One hundred simulations were run for all sequences. The PEP-FOLD3 results can be
interpreted as the propensity of an amino acid in the sequence to be in a helical, random coil or
extended strand structure. The structural results of the PEP-FOLD algorithm along with predicted 3D
conformations are also shown in Figures S13–S15.
Although PEP-FOLD3 predicts secondary structure propensity based on NMR structures recorded
mostly in aqueous solutions [37], the resulting predicted structures for 20mer peptides within region
214–255 correspond with the structure of the regions in the protein, and also with the structure
measured by ECD in TFE or aqueous TFE, but not in water (Figures S14 and S15). Region 219–238 is an
exception is this region, its predicted structure displays only minor helical content while in the protein
larger portion of it adopts helical structure. In the case of the N-terminal -5–15 and -1–19 region the
high helix-content predicted corresponds to ECD measurements in TFE or aqueous TFE, but not to the
known 3D structure (Figure S13). It must be noted that structure 1JMA (HSV-1 gD – HVEM complex)
is the only structure available that contains this part of the protein, and in this structure the region 7–17
is in complex with the HVEM. In all other known HSV-1 gD structures this region is invisible due to its
unordered conformation.
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3.3. Cellular Uptake and Intracellular Localisation of HSV-1 gD Cf-Peptides
HSV-1 establishes primary infection in epithelial cells through entry at skin and mucosal sites.
In addition to replication at the peripheral epithelium, HSV-1 is able to establish infections in the
peripheral nervous system. Neuronal cells harbour the virus in latent phase, and these cells play a
pivotal role in persistent infection and cannot be ignored. HSV-1 can reactivate at any time in response
to stimuli (physical, emotional stress or compromised immunity) [38,39]. Therefore, neuronal cell line
can be employed as a suitable model to investigate the main features of the designed carrier peptides.
Internalisation of the peptides was measured on SH-SY5Y human neuroblastoma culture [25–28],
which was chosen as a neuronal host cell model [38–41].
Measurements using BD LSR II flow cytometer revealed a concentration-dependent internalisation
of the Cf-HSV peptides. The peptide derivatives internalised into host cell model SH-SY5Y human
neuroblastoma cells in a dose-dependent manner, characterised by the enhanced intracellular
fluorescence measured by BD LSR II flow cytometer. The percentage of Cf-positive (Cf+) live
cells with standard error of the mean is demonstrated in the Supplementary Information (Figure S16).
Cellular uptake at 10 µM concentration is presented in Figures 5 and 6.
The cell viability was also assessed by flow cytometry using propidium iodide (PI) exclusion
method. PI is a membrane impermeant dye that is excluded from viable cells. PI penetrates the
damaged, permeable membranes of non-viable cells and it is widely used for determination of
membrane integrity and quantification of cell viability. Relative viability after 3 h treatment with
Cf-HSV-1 gD Set IV peptides (as representatives) compared to untreated cells is shown in Figure S17.
Relative viability of the cells was above 85% for each Cf-peptide.
Significant differences have been observed between the cellular uptake of individual peptides. In
the manner of IC50 calculations, the UC50 value was introduced for a numeric representation of the
uptake. UC50 is the interpolated concentration required for intracellular fluorescence in 50% of the
cells (Table 1). For the interpolation of UC50 values see Supplementary Information Figure S18. UC50
determination required higher treating concentration (250 µM) in the case of some peptides (mainly Set
II peptides, also Cf-(4–23) from Set I and Cf-(236–255) from Set III) in Table 1 to identify these peptides,
see UC50 values higher than 50 µM.
In Set I, three overlapping 20mer peptides were chosen from the N-terminal of the HSV-1 gD
glycoprotein which are only partly visible on the complex structures of either HSV-1 gD – nectin or
HSV-1 gD – HVEM. Further two N-terminal peptide sequences based on the structure of the HSV-1
gD – nectin complex (20–39, 23–42), and a sequence based on the structure of the HSV-1 gD – HVEM
complex (10–33) and its N- and C-terminal decamers were prepared and studied for their cellular
uptake (Figure 5A, Figure S16a,b). Except for peptide Cf-(4–23) (UC50 ~ 90 µM), these entered SY5Y
cells with UC50 values between 17 and 40 µM. Peptide Cf-(4–23) showed low internalisation even at
c = 250 µM, 63% Cf positive live cells. The highest internalisation ability among these peptides was
observed in case of Cf-(-1–19) peptide (UC50 = 17.5 µM), at c = 10 µM the Cf-positive live cells exceeded
25%. Peptide Cf-(10–33) and its N- and C-terminal decamers showed mediocre internalisation (UC50
values were between 30 and 40 µM). This peptide covers two regions in close proximity with HVEM
connected by a hairpin structure in the HSV-1 gD – HVEM complex. Both the N-terminal Cf-(10–19)
and C-terminal Cf-(24–33) peptides internalised with slightly higher efficiency than the parent peptide,
Cf-(10–33). Higher fluorescence intensity was observed, but in smaller percentage of cells in case of the
possibly nectin-1 binding Cf-(20–39) and Cf-(23–42) peptides.
A series of 20mer peptides (Set II) from the central part of HSV-1 gD (181–216) was found to have
very poor internalisation efficiency, with the exception of Cf-(181–200) with mediocre internalisation
(UC50 = 36.8 µM), their UC50 values were above 50 µM, in case of Cf-(193–212) and Cf-(197–216) above
100 µM (Figure 5B, Figure S16c,d). Even in c = 250 µM, the percentage of Cf positive live cells was
generally under 80%.
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When the nectin-1 binding C-terminal region of HSV-1 gD (Set III) was analysed with overlapping
20mer peptides, we found peptides with strong internalisation ability (Figure 6A,B). The highest cellular
uptake among them was observed in case of Cf-(228–247), followed by Cf-(224–243) and Cf-(219–238)
(UC50 = 4.7, 6.6 and 12.2 µM, respectively). Even in c = 2 µM concentration these peptides resulted in
15–20% of Cf-positive live cells. Towards both N- and C-termini the internalisation gradually decreased.
From these results the sequence 228–243, the common sequence between 228–247 and 224–243 has been
deduced as participating most in the cellular entry, and peptide Cf-(228–243) proved to be also effective
with UC50 = 6.5 µM, although the mean fluorescence intensity was lower. It should be noted that the
fluorescence intensity of this peptide, measured by fluorimetry, was also lower. The common sequence
between the second and third most effectively internalising peptides, 224–239 was also examined, but
Cf-(224–239) was found to have lower internalising ability (UC50 = 23.7 µM) than either of its parent
peptides. Therefore, peptides derived from the 228–243 sequence were examined further.
Examination of the cellular entry ability of set IV peptides – modified and/or truncated variants of
Cf-(228–247) – revealed that Trp241 may be substituted for Phe without significant loss of internalisation
ability (Cf-(228–247): 4.7 µM vs. Cf-(228–247 F): 10.5 µM, Cf-(224–243): 6.5 µM vs. Cf-(228–243 F):
8.9 µM UC50). N-terminally truncated versions of peptide Cf-(228–243 F) have also been examined, but
we have observed that their cellular uptake was lower than that of the parent peptide, resulting in
UC50 values between 12 and 20 µM (Figure 6C,D, Figure S16e,f).
Not only Trp241Phe, but also Lys237Arg exchange was performed systematically in the 228–243
sequence. As seen in Figure 6C,D and Figure S16e,f, these modifications did not decrease the
internalisation rate of these peptides (UC50 values were between 6 and 9 µM).
The cellular uptake of HSV-1 gD peptides has been compared with a tuftsin peptide (OT10) and a
cell penetrating peptide, Penetratin. OT10 is a non-membrane-active, receptor binding peptide, which
represents cationic character. Penetratin is a membrane-active, amphiphilic cell penetrating peptide
(cpp) with superior penetration ability and low in vitro toxicity on human cells.
Tuftsin is a natural peptide produced by enzymatic cleavage of the Fc-domain of the heavy
chain of immunoglobulin G. During the past decade, a new group of sequential oligopeptide carriers
with discrete molecular masses has been developed in our laboratory: these oligotuftsin derivatives
consisting of tandem pentapeptide repeat unit [TKPKG]n (n = 2, 4, 6 and 8) are based on the canine
tuftsin sequence TKPK. These compounds are nontoxic and non-immunogenic and are developed
to be effective tuftsin-receptor specific carrier peptides [42,43] to deliver, e.g., antitubercular drug
candidates into monocytic host cells [20,44]. In this study, we have compared the internalising ability of
Cf-TKPKGTKPKG (Cf-OT10) peptide with that of HSV-1 gD peptides on SH-SY5Y cells (comparison of
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Set II peptides and OT10 is shown in Figure S19). There are no tuftsin receptors on SH-SY5Y cells [45].
Although in large concentration (c = 50 µM) OT10 shows effective cellular uptake, though not reaching
100%, in low c = 10 µM concentration it did not reach the level of internalisation of HSV peptides even
with moderate uptake level.
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Figure 6. Internalisation of synthetic gD peptides into SH-SY5 neuroblastoma cells measured
by flow cytometr . (A) Internalisation of Set III peptides at c = 2, 10 and 5 µM, percentage of Cf-positive
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internalisation of Set IV peptides at c = 10 µM, ercentage of Cf-positive live cells, (D) internalisation
of Set IV peptides at c = 10 µM, mean fluorescence intensity. Graphs were plotted using Origin 2018
(OriginLab, Northampton, MA, USA).
Cpps and their numerous s nthetic derivatives are the focus of research and potential drug
delivery applications. These cpps are promising chemical helpers to transport non-permeable drugs
into live cells [17,46–50]. One of the most studied cpp is Penetratin, which was derived from the
sequence of HIV transactivator protein [51] and the third helix of the homeodomain of Drosophila
Antennapedia protein [52] Peptide Cf-(228–247) internalised in a comparable way with Cf-Penetratin
(Figure S20).
Parallel with flow cytometry measurements to assess qualitative information regarding the
subcellular localisation, the internalised Cf-(228–243 F) (with UC50 = 8.9 µM) was imaged by confocal
laser scanning microscopy. To visualise intracellular localisation of the Cf-peptides, LysoTrackerTM
Deep Red was used for lysosome and Hoechst 33342 for nuclear staining. As a peptide with low
internalisation rate, Cf-(236–255) (UC50 = 65.7 µM) was also investigated. The experiment was
carried out with 3 h incubation time and only representative images are shown (Figure 7). As was
expected based on the results of flow cytometry measurements, in the case of peptide Cf-(236–255) no
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internalisation occurred, no trace of fluorescent signal was observed in the cytosol and in lysosomal
compartments (Figure 7A, upper panels). Peptide Cf-(228–243 F) could be imaged in the cytosol
and the nucleus, but there is no co-localisation with lysosomal staining (Figure 7A, lower panels).
This suggests that there is no vesicular transport involved in the uptake of the Cf-peptide (no direct
co-localisation with lysosomes). The Cf-peptide internalises and displays a ubiquitous distribution in
the cytosol and in the nucleus as well. Since the Cf signal only partially co-localises with the lysosomes
this pathway could be deemed negligible (presented at Figure 7B, enlargements).Biomolecules 2020, 10, 15 of 21 
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4. Discussion
The ECD spectroscopic results are in good agreement with the cell internalisation data presented.
The best UC50 values (UC50 < 10 µM) were obtained for peptides Cf-(224–243) and Cf-(228–247) whose
acetylated counterparts exhibit pronounced helical folding in the membrane mimicking solvent TFE,
also peptide Cf-(228–243) and its W→F and K→R derivatives, of which Ac-(228–243 F) showed similar
structural characteristics to the above two peptides. Conversely, sequences associated with little helical
character even in pure TFE such as Ac-(214–233), Ac-(232–251) and Ac-(236–255) (Figure 8, Table 2)
showed decreasing internalisation rates. Cf-peptide of the 219–238 sequence has relatively high, but not
outstanding internalization rate, while Ac-(219–238) also showed lower helical content than peptides
of the 224–247 region. The relationship between the helical propensity of the peptides and their cellular
uptake is demonstrated in Figure 8A. Among the peptides in the nectin-1-binding region of HSV-1 gD,
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we found that the higher the helix content in TFE is, the higher the cellular entry rate is (the lower the
UC50 value). For visualisation, in Figure 8B the UC50 values of Set III peptides are contrasted with
their PEP-FOLD3 secondary structure prediction structures.Biomolecules 2020, 10, 16 of 21 
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of Cf-peptides, data were obtained from cellular uptake studies (Table 1). (B) PEP-FOLD3 predicted
secondary structure of HSV peptides (Figures S14 and S15), the prediction method refers structures in
mostly aqueous solutions [21,37].
A possible explanation of the differences between the peptides’ uptake rate may be based on
mainly conformational features. Our data suggest that the helicity of the peptides is the most important
factor in the process of internalisation. This hypothesis can be supported by the above presented
parallel between internalisation (quantified by UC50) and helical content (Figure 8).
The most effectively internalising peptides contain only 5 residues of HSV-1 gD (230TV231, 234YS235
and I238) which are in close contact with nectin-1 according to the crystal structure of the complex
(Figure 9A, red parts of the helix) and not the 214–227 region, which has several more contacting
residues in a loop and a β-strand region [4,5]. On the other hand, interaction of parts of this region
with nectin-1 may also promote the internalisation of certain peptides. Therefore, we have analysed
the internalisation of peptides from the 214–243 region in the light of the localisation of this region in
the 3D structure of HSV-1 gD and nectin-1 complex (Figure 9B).
Peptides Cf-(228–43), Cf-(224–243) and the 16mer Cf-(228–243) deduced from their sequence
all showed higher internalising rate than Cf-(219–238) (UC50 = 12.2 µM), therefore the sequence
239AGWHG243 probably plays a role in the sequence requirements for effective cellular uptake.
According to the HSV-1 gD – nectin-1 complex X-ray structure [6,9], 239AGWHG243 is not participating
in this interaction, but 240GWHG243 folds back on the 234–239 helical region (Figure 9B) and may
promote or stabilise the suitable peptide conformation for internalisation. Another 16mer peptide,
Cf-(224–239), containing the common sequence of Cf-(224–243) and Cf-(219–238) was expected to have
similar uptake ability to its parent peptides, but the determined internalisation level was significantly
lower (UC50 = 23.7 µM). Thus, the presence of 219MLPRF223 markedly increased the cellular uptake of
peptide Cf-(219–238) compared to the 16mer. These residues in the complex structure form an extended
conformation in close contact with the C”C’CFG β-sheet of nectin-1 (Figure 9B). It can be hypothesised
that in case of peptides containing this region the cellular entry is mediated by a possible attachment to
nectin-1, resulting in accumulation of the peptide on the cell surface, prior to the internalisation. The
nucleus is one of the most important organelles in eukaryotic cells. Targeted nuclear delivery is an
increasing and important area of drug delivery and gene therapy related research. Our data suggest
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that peptide Cf-(228–243 F) possesses nuclear internalisation ability. This phenomenon can be explained
by the finding that the region 228–247 contains nuclear localisation signal pattern (WHGPKA) and
shares a homologue sequence with the 52WTGVEA57 sequence of the HIV-1 Vpr52–93 sequence which
was proven to internalise [53]. Using the approach described by Kanduc [54], we also determined
a short sequence within this peptide (KIA) which is homologous with adenoviral Ad3 fibre protein
derived nucleus targeting peptide.
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Figure 9. 3D structure of HSV-1 gD glycoprotein (grey) in complex with nectin-1 (ocean green). (A)
the ribbon indicates the region covered by Set III peptides, red parts participate in the HSV-1 gD –
nectin-1 interaction. (B) Details of the binding surface with HSV-1 gD 214–243 region are in stick
representation, red residues are in contact with nectin-1. After the strongly binding 214–223 segment
(red) the non-contacting 224IPENQR229 segment can be seen (blue), then 230TVAVYSLKI238 helical
region with alternating contacting and non-contacting residues. Segment 240GWHG243 (blue) is folding
back on the helical region.
The topic of our next study will be to assess the exact mechanism of the cellular entry process and
the intracellular trafficking of the peptides.
5. Conclusions
Ligand-targeted delivery can improve the cellular uptake of different cargoes (i.e., drugs)
through specific binding to receptors that are expressed or even overexpressed on a particular
target cell surface. Large number of targeted ligands have been discovered for cell directed delivery,
such as peptides and antibodies. Therefore, identifying potential new carrier peptides from viral
proteins is a novel available tool. These peptides possess favourable internalisation properties and
they can be promising candidates in the development of innovative delivery vehicles and reliable
alternatives to other type of carrier peptides. In this study, we have demonstrated that 16mer and
20mer peptides derived from the nectin-1 binding region of the HSV-1 gD glycoprotein are able
to internalise in SH-SY5Y neuroblastoma cells with high efficiency. The most potent peptides are
corresponding to the 224IPENQRTVAVYSLKIAGWHGPKAP247 sequence of HSV-1 gD, and most
of that part has helical conformation within the protein. These peptides show a tendency of
forming helical structure in lipomimetic TFE solution as well. Overall, it can be concluded that
the disorder-to-helix conformational transition of HSV-1 gD peptides is a decisive structural feature for
their cell entry mediated by biomembrane or nectin-1 interactions. As lead sequences for further studies
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228QRTVAVYSLKIAGWHGPKAP247 or 228QRTVAVYSLKIAGWHG243 were indicated, with Lys237Arg
and/or Trp241Phe substitutions for stability and side-reaction free conjugation of cargo molecules.
We plan a comprehensive study for evaluating the cellular entry mechanism and intracellular
trafficking of HSV-1 gD peptides.
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